The largest database of trusted experimental protocols

8 protocols using poziotinib

1

Cytotoxicity Assays Investigating ERBB4 Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Ba/F3 cells (20,000 cells/well) expressing ERBB4 variants were plated on 96-well plates in RPMI1640 medium containing 10 ng/mL NRG-1. Vector control cells were plated in RPMI1640 medium containing 5% WEHI conditioned medium. The cells were incubated in the presence or absence of 0.0005–10 µmol/L erlotinib (Santa Cruz Biotechnology), afatinib (Boehringer Ingelheim), neratinib (SantaCruz Biotechnology), dacomitinib (Cayman Chemicals), poziotinib (Selleck Chemicals), ibrutinib (Selleck Chemicals), or lapatinib (Santa Cruz Biotechnology), for 72 hours before measuring the viability of cells with MTT assay (described above). Sigmoidal dose–response curves were fitted using asymmetric five-parameter non-linear regression in GraphPad Prism 9 and are graphically displayed with GraphPad Prism 9. The IC50 values are calculated with the help of the R package “drc” (34 (link)) by using quadruplicate measurements from the MTT assay for the indicated concentrations from 3–5 individual experiments and fitting four-parametric log-logistic models (LL.4, LL2.4; R). The unpaired t test (Welch two-sample t test) was used to compare IC50 values.
+ Open protocol
+ Expand
2

Comprehensive Kinase Inhibitor Screening

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following commercial compounds were used in this study: AG1478 (Selleckchem, S2728), canrenone (Santa Cruz, sc-205616), clozapine (Sigma-Aldrich, C6305), erlotinib (Sigma-Aldrich, SML2156), gefitinib (Sigma-Aldrich, SML1657), lapatinib (Selleckchem, S1028), osimertinib (Selleckchem, S7297), poziotinib (Selleckchem, S7358), pyrotinib (MedChemExpress, HY-104065), spironolactone (Selleckchem, S4054), TAS6417 (Selleckchem, S8814), EGF (Sigma-Aldrich, E9644, EGF-like domain (Sigma-Aldrich, H7660), serotonin (Tocris, 3547). Compounds A and B were synthesized by the Department of Medicinal Chemistry of the Lead Discovery Center, Dortmund, Germany, as part of a proprietary kinase inhibitor program.
+ Open protocol
+ Expand
3

Acquisition and Storage of Tyrosine Kinase Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lapatinib, afatinib, dacomitinib, osimertinib, rociletinib, nazartinib, ibrutinib, and poziotinib were purchased from Selleck Chemical. Erlotinib and gefitinib were obtained from the institutional pharmacy at The University of Texas MD Anderson Cancer Center. Olmutinib was provided by Boehringer-Ingelheim. All inhibitors were dissolved in DMSO at a concentration of 10 mM and stored at –80 °C.
+ Open protocol
+ Expand
4

Generating EGFR Exon 20 Mutant Ba/F3 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
The interleukin‐3–dependent murine pro–B‐cell line Ba/F3 was provided by Riken Bio Resource Center. Cells were cultured in RPMI 1640 medium (Wako) with 10% FBS (Sigma‐Aldrich). EGFR‐TKIs (afatinib, poziotinib, and osimertinib) were purchased from Selleck Chemicals. Tarloxotinib and tarloxotinib‐E were provided by Rain Therapeutics, Inc. Mycoplasma contamination was checked routinely using the TaKaRa PCR Mycoplasma Detection Set (Takara).
Each EGFR exon 20 mutation was introduced into the Ba/F3 cells by retroviral vectors as previously described.13 We generated A763insFQEA, D770insSVD, and H773insNPH mutations from full‐length complementary DNA that encoded the wild‐type EGFR gene (Addgene), using the Prime STAR Mutagenesis Basal Kit (Takara) with specific primers (Table S1). Full‐length complementary DNA that encoded V769insASV and H773insH was purchased from Addgene. We also used Ba/F3 cells with secondary mutations, plus either EGFR exon 19 deletion or L858R point mutation, which our previous study showed to be potential factors in resistance to frontline osimertinib.13
+ Open protocol
+ Expand
5

Evaluating Compounds by Flow Cytometry

Check if the same lab product or an alternative is used in the 5 most similar protocols
We individually validated 8 compounds in same concentration (20 μM). Here, we exposed the drug for 16 h either at 32 or 37°C, and evaluated by flow cytometry as previously described. In a 96-well plate 20,000 of either 293 or 293+SP1-MHI cells were seeded per well in a total volume of 200 μL of media. After cells had attached to the wells (the morning after), cells were exposed to 20 μM of each drug, controls were exposed to the same quantity of DMSO as drug, for 16 h and harvested for flow cytometry analysis. Flow cytometry analysis was conducted as previously described. Drugs that were tested for further validation after initial screen were: Orantinib (Selleckchem, S1470), Dasatinib (Selleckchem, S7782), Poziotinib (Selleckchem, S7358), Tamoxifen Mylan (Mylan AB*), Erythromycin (Stragen Pharma GmbH*), Naloxone (B. Braun*), Entacapone (Orion Corporation*) and Cinacalcet (Ratiopharm GmbH*). Drugs labeled with “*” were pharmaceutical grade medications gifted from the Pharmacy at Landspítali University Hospital. Analysis was performed as described above.
+ Open protocol
+ Expand
6

Evaluating Small Molecule Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
AG-1478 (Selleckchem Cat# S2728), Poziotinib (Selleckchem, Cat# S7358) SD208 (Sigma, Cat# S7071) and U0126 (Cell Signaling Technology, Cat. # 9903) were reconstituted in DMSO (Vehicle).
+ Open protocol
+ Expand
7

HER2-targeting Antibody Immunoblotting

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies used for immunoblotting were purchased from Cell Signaling Technologies: phospho-HER2 (1248), phospho-p44/42 MAPK (Thr202/Tyr204), p44/42 MAPK, phospho-Akt (Ser473), Akt, phospho-S6 (240-44 (link)), phospho-S6 (235-236), phospho-MTOR, phospho-S6 (Thr 389), E-Cadherin (24E10); from Millipore: phosphoHER2 (pY1248); from Sigma: monoclonal Anti-β-Actin; and from Thermo Fisher: HER2 antibody (Ab-17). Poziotinib and tucatinib were obtained from Selleckchem. Pyrotinib was obtained from MedChem Express. Neratinib was provided by Puma Biotechnology, Inc., under a Materials Transfer Agreement.
+ Open protocol
+ Expand
8

Tarloxotinib and EGFR TKIs Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Tarloxotinib and its activated drug, tarloxotinib-E, were provided by Rain Therapeutics Inc. We also used afatinib, poziotinib [second-generation (2G) EGFR TKIs], osimertinib [third-generation (3G) EGFR TKIs], and pyrotinib, which were purchased from Selleck Chemicals (Houston, TX, USA). Each drug was dissolved to a concentration of 10 mmol/L in dimethyl sulfoxide (DMSO, Sigma-Aldrich) and stored at −80 °C until use.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!